Literature DB >> 15207614

Quantification of virus-envelope-mediated cell fusion using a tetracycline transcriptional transactivator: fusion does not correlate with syncytium formation.

Wu Ou1, Ying Xiong, Jonathan Silver.   

Abstract

Cell fusion occurs in many cellular processes and viral infections. We developed a new, quantitative cell fusion assay based on the tetracycline-controlled transactivator (tTA)-induced expression of a luciferase reporter gene. The assay is objective, sensitive, linear over 2-3 orders of magnitude, amenable to microtiter-plate format, and generalizable to study fusion mediated by a variety of genes. Applied to HIV and MLV, cell fusion paralleled virus entry in terms of co-receptor requirements, need for post-translational processing of envelope, and complementation of SU mutations by soluble receptor-binding domain. However, biochemically measured fusion did not correlate with syncytia detected by standard light microscopy. When the assay indicated cell fusion occurred but overt syncytia were not observed, confocal microscopy using fluorescent protein markers showed that fusion was limited mainly to pairs of cells. Such nonprogressive cell fusion suggests that post-translational processing of envelope may be altered in heterokaryons co-expressing envelope and receptor.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15207614     DOI: 10.1016/j.virol.2004.02.032

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  9 in total

1.  Stoichiometry of murine leukemia virus envelope protein-mediated fusion and its neutralization.

Authors:  Wu Ou; Jonathan Silver
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

2.  Inhibition of murine leukemia virus envelope protein (env) processing by intracellular expression of the env N-terminal heptad repeat region.

Authors:  Wu Ou; Jonathan Silver
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

3.  Multiparametric assay to screen and dissect the mode of action of anti-human immunodeficiency virus envelope drugs.

Authors:  Julià Blanco; Imma Clotet-Codina; Berta Bosch; Mercedes Armand-Ugón; Bonaventura Clotet; José A Esté
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

4.  A Hydrophobic Target: Using the Paramyxovirus Fusion Protein Transmembrane Domain To Modulate Fusion Protein Stability.

Authors:  Chelsea T Barrett; Stacy R Webb; Rebecca Ellis Dutch
Journal:  J Virol       Date:  2019-08-13       Impact factor: 5.103

5.  Effect of epitope position on neutralization by anti-human immunodeficiency virus monoclonal antibody 2F5.

Authors:  Wu Ou; Ning Lu; Sloane S Yu; Jonathan Silver
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

6.  Imaging single retrovirus entry through alternative receptor isoforms and intermediates of virus-endosome fusion.

Authors:  Naveen K Jha; Olga Latinovic; Erik Martin; Gennadiy Novitskiy; Mariana Marin; Kosuke Miyauchi; John Naughton; John A T Young; Gregory B Melikyan
Journal:  PLoS Pathog       Date:  2011-01-20       Impact factor: 6.823

7.  Intracytoplasmic maturation of the human immunodeficiency virus type 1 reverse transcription complexes determines their capacity to integrate into chromatin.

Authors:  Sergey Iordanskiy; Reem Berro; Maria Altieri; Fatah Kashanchi; Michael Bukrinsky
Journal:  Retrovirology       Date:  2006-01-12       Impact factor: 4.602

8.  Micro-fusion inhibition tests: quantifying antibody neutralization of virus-mediated cell-cell fusion.

Authors:  Nazia Thakur; Carina Conceicao; Ariel Isaacs; Stacey Human; Naphak Modhiran; Rebecca K McLean; Miriam Pedrera; Tiong Kit Tan; Pramila Rijal; Alain Townsend; Geraldine Taylor; Paul R Young; Daniel Watterson; Keith J Chappell; Simon P Graham; Dalan Bailey
Journal:  J Gen Virol       Date:  2020-10-15       Impact factor: 3.891

9.  HIV coreceptor tropism determination and mutational pattern identification.

Authors:  Hui-Shuang Shen; Jason Yin; Fei Leng; Rui-Fang Teng; Chao Xu; Xia-Yu Xia; Xian-Ming Pan
Journal:  Sci Rep       Date:  2016-02-17       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.